{
  "id": 684695,
  "title": "Intuitive Surgical director Gary Guthart sells $4m in stock",
  "url": "https://urgent.news/2026/08/12/intuitive-surgical-director-gary-guthart-sells-4m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-12T17:45:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/intuitive-surgical-director-gary-guthart-sells-4m-in-stock-93CH-4855824"
  },
  "original_language": "en",
  "account": "Intuitive Surgical director Gary Guthart sold $4 million worth of the company's shares on August 11, 2026. The transaction, conducted under a pre-approved trading plan per SEC Rule 10b5-1, expired on June 15, 2027. The sale comprised 10,000 shares, each priced at $400. Currently, Intuitive Surgical holds a P/E ratio of 46.18 and a market capitalization of $142.26 billion. This places the company as a key player in the healthcare equipment sector. Following the sale, Mr. Guthart directly owns 1,245,679 shares, with 15,720 shares indirectly held by two trusts for the benefit of his children. Analysts at InvestingPro have rated the stock as potentially undervalued, with 21 analysts raising their earnings forecasts for the upcoming period. Despite positive financial results, Bernstein SocGen Group has lowered its price target to $685, citing potential challenges in U.S. growth. Conversely, Oppenheimer has upgraded the stock to \"Outperform,\" while UBS initiated coverage with a \"Buy\" rating. BMO Capital also maintains an \"Outperform\" rating, acknowledging Intuitive Surgical's strong performance but noting a slower growth rate in U.S. da Vinci procedures.",
  "summary": null,
  "key_points": [
    "Gary Guthart sold $4 million worth of Intuitive Surgical shares on August 11, 2026.",
    "The sale of 10,000 shares at $400 each expired on June 15, 2027.",
    "Analysts rate the stock as potentially undervalued, with Bernstein lowering price target to $685."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock",
        "url": "https://urgent.news/2026/08/13/hepion-pharmaceuticals-interim-ceo-gary-stetz-buys-100-000-in-stock",
        "published": "2026-08-13T03:01:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}